

Peptic Ulcer Drugs Market Insights Growth During the Forecast Period

Market Overview

Peptic Ulcer Drugs Market Size was valued at USD4.2 billion in 2022 and to grow from USD 4.4 Billion in 2023 to USD 5.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.80% during the forecast period (2023 – 2030).

Market Highlights

During the forecast period, the global [demand for peptic ulcers](#) is projected to rise at a quick rate. Peptic ulcers can be caused by lifestyle-related causes such as aerated beverages, alcoholism, fatty food intake, and stress. This is a significant force that propels the worldwide demand for peptic ulcers. Peptic ulcers in the geriatric community can cause serious morbidity. Therefore, the growth of this demographic is a key factor expected during the forecast period to drive the demand. In addition, the rise in the patient population and the increase in opioid intake, such as aspirin, ibuprofen and other inflammatory medications, are the other reasons that are likely to increase the global demand for peptic ulcers. Factors such as the rising smoking prevalence are also anticipated to encourage the widening of the global demand for peptic ulcer medications over the projected period.

Because of the current COVID-19 pandemic-an acute respiratory distress syndrome triggered by the novel coronavirus-the most unparalleled institutional and economic problems have arisen. Furthermore, for the production and commercialization of appropriate treatment options for this new COVID-19 pathogen, a substantial amount of time is needed. It is projected that these joint infection transmission and management issues will hinder the diagnosis and treatment of GI-disease in the coming quarters of 2020 and 2021. Owing to the prioritisation of COVID-19 care, decreased doctor and hospital visits for non-essential health conditions would hinder market development. Due to the availability of COVID-19 vaccines, the market for peptic ulcer medications is expected to return to pre-pandemic market demand in 2021. This will be mirrored in the rebound from the COVID-19 pandemic in developing and emerging economies. In addition, local officials are prioritising healthcare services to meet the complexities of COVID-19, which is also likely to slow down the short-term growth of the demand for peptic ulcer medications.

Nevertheless, the adverse effects of peptic ulcer medications, low pipeline efficiency, and changes in drug pricing policies are factors that are likely to impede the development of the global peptic ulcer drug industry in the coming years.

Competitive Dashboard

Daiichi Sankyo Company Limited,

Novartis AG,

Acetelion Ltd.,

Sanofi S.A.,

Boehringer Ingelheim,

Astra Zeneca plc,

Takeda Pharmaceuticals Company Limited,



